Trial Data Project

Steps Followed to Extract the Trial Data

Extracting Data from XML Files

All the historical USPTO data is available as XML files. Here is the tree structure for the XML files:

-<clinical_study rank="61205">
    +<required_header>
    +<id_info>
    <brief_title>
    +<sponsors>
    <source>
    +<oversight_info>
    +<brief_summary>
    +<detailed_description>
    <overall_status>Completed</overall_status>
    <phase>Phase 1/Phase 2</phase>
    <study_type>
    <study_design>
    <condition>
    +<intervention>
    +<eligibility>
    +<location>
    +<location_countries>
    <verification_date>
    <lastchanged_date>
    <firstreceived_date>
    <has_expanded_access>
    +<condition_browse>
    +<intervention_browse>

Corresponding tables are:

• Study
• Location
• Sponsors
• Eligibility
• Dates
• MeSH (Medical Subject Headings)

Study

The corresponding nodes are:

-<id_info>
    <org_study_id>NCRR-M01RR01070-0506</org_study_id>
    <secondary_id>M01RR001070</secondary_id>
    <nct_id>NCT00000102</nct_id>
</id_info>

<brief_title>Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets</brief_title>

-<oversight_info>
    <authority>United States: Federal Government</authority>
</oversight_info>

-<brief_summary>
    <textblock> This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH). </textblock>
</brief_summary>

-<detailed_description>
    <textblock> This protocol is designed to assess both acute and chronic effects of the calcium channel antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone (ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects. The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can attenuation of ACTH release by nifedipine permit a decrease in the dosage of glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce the deleterious effects of glucocorticoid treatment in CAH. </textblock>
</detailed_description>

<overall_status>Completed</overall_status>

<phase>Phase 1/Phase 2</phase>

<study_type>Interventional</study_type>

<study_design>Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>

<condition>Congenital Adrenal Hyperplasia</condition>

Location

The corresponding node is:

-<location>
    -<facility>
        <name>Medical University of South Carolina</name>
        -<address>
            <city>Charleston</city>
            <state>South Carolina</state>
            <country>United States</country>
        </address>
    </facility>
</location>

Sponsors

The corresponding node is:

-<sponsors>
    -<lead_sponsor>
        <agency>National Center for Research Resources (NCRR)</agency>
        <agency_class>NIH</agency_class>
    </lead_sponsor>
</sponsors>

Eligibility

The corresponding node is:

-<eligibility>
    -<criteria>
        <textblock> Inclusion Criteria: - diagnosed with Congenital Adrenal Hyperplasia (CAH) - normal ECG during baseline evaluation Exclusion Criteria: - history of liver disease, or elevated liver function tests - history of cardiovascular disease </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
</eligibility>

Dates

The corresponding nodes are:

<verification_date>January 2004</verification_date>

<lastchanged_date>June 23, 2005</lastchanged_date>

<firstreceived_date>November 3, 1999</firstreceived_date>

MeSH

The corresponding nodes are:

-<condition_browse>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
</condition_browse>
-<intervention_browse>
    <mesh_term>Nifedipine</mesh_term>
</intervention_browse>